IN8bio (INAB) Expected to Announce Earnings on Thursday

IN8bio (NASDAQ:INAB) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

IN8bio Price Performance

Shares of INAB stock opened at $0.24 on Wednesday. The stock’s fifty day moving average is $0.28 and its 200-day moving average is $0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $19.73 million, a PE ratio of -0.32 and a beta of 0.03. IN8bio has a 52 week low of $0.22 and a 52 week high of $1.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of IN8bio in a report on Wednesday, February 12th.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.